|
Vol. 97, Issue 2, 841-846, January 18, 2000
* Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599-7525, and § Department of Pathology, University of Texas Health Science Center, San Antonio, TX 78284-7750
Communicated by Oliver Smithies, University of North Carolina, Chapel Hill, NC, November 30, 1999 (received for review November 12, 1999)
| |
Abstract |
|---|
|
|
|---|
By inactivating the gene for
L-gulono-
-lactone oxidase, a key enzyme in ascorbic acid synthesis, we have generated mice that, like humans, depend
on dietary vitamin C. Regular chow, containing about 110 mg/kg
of vitamin C, is unable to support the growth of the
mutant mice, which require L-ascorbic acid supplemented in their
drinking water (330 mg/liter). Upon withdrawal of supplementation,
plasma and tissue ascorbic acid levels decreased to 10-15% of normal within
2 weeks, and after 5 weeks the mutants became anemic, began to lose weight, and die. Plasma total antioxidative capacities were approximately 37%
normal in homozygotes after feeding the unsupplemented diet for 3-5
weeks. As plasma ascorbic acid decreased, small, but
significant, increases in total cholesterol and decreases in high density
lipoprotein cholesterol were
observed. The most striking effects of the marginal dietary vitamin C were alterations in the wall
of aorta, evidenced by the
disruption of elastic laminae,
smooth muscle cell proliferation, and focal endothelial desquamation of
the luminal surface. Thus, marginal
vitamin C deficiency affects the vascular integrity of mice unable to synthesize ascorbic acid, with potentially profound
effects on the pathogenesis of
vascular diseases.
Breeding the vitamin C-dependent mice with mice carrying defined genetic mutations will provide numerous
opportunities for systematic studies of the role of antioxidants in
health and disease.
| |
Introduction |
|---|
|
|
|---|
Oxygen-derived free radicals are inevitable byproducts of normal biological functions such as respiration, energy generation, biosynthesis of macromolecules, and protection against infections. Normally, free radicals are swiftly destroyed by various antioxidant enzymes and small antioxidant molecules, which the body produces to prevent free radicals from reacting with lipids, proteins, and nucleic acids. Failure to maintain a coordinated balance between the production of free radicals and defenses against them can lead to cell death, tissue injury, and disease. Thus, much attention has been given in recent years to oxidative stress as a potentially important factor in the pathogenesis of many diseases, including atherosclerosis, cancer, and neurodegenerative diseases (1-4).
Studies of the pathogenesis of human diseases have benefited from the
availability of small laboratory
animal models for many years. Mutant mice are particularly useful for investigating the
interplay of genetic and
environmental factors in the pathogenesis of
common, but multifactorial, diseases (5).
However, there is a major handicap for studies involving the endogenous
redox systems of humans and mice: humans (and other primates) lack the ability to synthesize ascorbic acid because of a loss of function in the gene (Gulo)
coding for a key synthetic enzyme, L-gulono-
-lactone oxidase (6),
whereas mice have the functional gene. As a consequence, mouse tissues generally
have high levels of ascorbic acid, which are only slightly
influenced by exogenous vitamin C. In contrast, humans depend
entirely on vitamin C derived from the diet. Guinea
pigs also have lost this enzyme function and depend on dietary
vitamin C (7).
Hence severe deficiency of vitamin C causes disease (scurvy) in both primates and guinea pigs. A
strain of rats (ODS, Osteogenic Disorder Sionogi, ref. 8)
also has a defect in the
same gene (9).
No mouse strain is known with this deficiency, yet such mice, in which vitamin C intake can be controlled by diet, would be particularly valuable for investigating
the interplay between endogenous and exogenous redox systems,
genetic factors, and various diseases. To this end, we have generated
Gulo
/
mutant mice, and we here describe the effects of vitamin C deficiency on three factors influential in vascular disease: plasma
antioxidative capacity, plasma lipoprotein levels, and
vascular integrity.
| |
Materials and Methods |
|---|
|
|
|---|
Gene Targeting. Using published sequences of the rat Gulo gene (7), we isolated a phage clone spanning exons 3-7 of the mouse Gulo gene (Fig. 1A). The targeting construct (Fig. 1B) was designed to modify the locus so that a neomycin resistance gene replaces exons 3 and 4. A 6-kb EcoRI fragment containing exons 5-7 provided a 3' arm of homology, and a 1.4-kb EcoRI/BamHI fragment in intron 2 formed a 5' arm of homology. The neomycin resistance gene (pMC1neo) and the Herpes simplex thymidine kinase gene (pGKTK) both are oriented oppositely from the transcriptional orientation of the Gulo gene in the construct.
|
Mice. Chimeras were generated as described (10) and mated with C57BL/6 mice. For genotyping by PCR, three primers, P2 described above, P3 (5'-GTCGTGACAGAATGTCTTGC-3'), and P4 (5'-GCATCCCAGTGACTAAGGAT-3') were used with tail DNA in a single reaction. A 230-bp fragment derived with P2 and P3 from the targeted locus and/or a 330-bp fragment derived with P3 and P4 from the endogenous locus distinguish homozygous, heterozygous, and wild-type animals.
Animals were handled as approved by the Institutional Animal Care and Use Committee. Mice were weaned at 3 weeks of age and fed ad libitum with irradiated mouse chow (PicoLab 5058, PMI Feeds, St. Louis). They had free access to water with or without vitamin C. The average ascorbic acid content of the diet was 110 mg/kg. To supplement vitamin C, drinking water was made to contain 330 mg L-ascorbic acid/liter and 0.01 mM EDTA and changed at least once a week. Heterozygous or homozygous mutant breeding pairs were kept on vitamin C supplementation for the production of homozygous pups, which were weaned onto vitamin C-supplemented water unless specifically stated. Heterozygotes were maintained on regular chow without ascorbic acid supplementation, unless specifically stated. All mice used in the current experiments were younger than 6 months old and had a mixed genetic background derived from the strains 129 and C57BL/6. Blood was obtained either from the retroorbital sinus or by heart puncture and was anticoagulated with heparin or EDTA. Mice were euthanized with an overdose of Avertin (2,2,2-tribromoethanol) followed by fixation of the vasculature with 4% paraformaldehyde through the left ventricle at a physiological pressure.Biochemical Measurements. Ascorbic acid levels were measured by the
,
'-dipyridyl method as described (11).
Antioxidative capacities of fresh plasma were
determined by an enhanced chemiluminescence assay, based on the
potential to quench light emission from a glowing
horseradish peroxidase-catalyzed enhanced chemiluminescence reaction (12).
The antioxidant activity was expressed by comparison with the quenching activity of a tocopherol-analogue, trolox. Lipid
peroxidation was assayed colorimetrically as free malonaldehyde plus
4-hydroxyalkenals by using a kit (Oxis International, Portland, OR)
according to the supplier's protocol. Plasma levels of cholesterol and triglycerides were determined
enzymatically with kits obtained
from Wako BioProducts
(Richmond, VA) and Sigma. High
density lipoprotein (HDL) cholesterol levels were
determined after removing apolipoprotein B-containing particles by magnesium/dextran precipitation method (13).
Fractionation of the
plasma lipoproteins by ultracentrifugation and SDS gel
electrophoresis of
apolipoproteins have been described
(14).
Hematological determinations were made with an
Animal Blood Counter
(ABC vet, ABX Hematology, Garden Grove CA).
Microscopic Examination. For transmission electron microscopy (TEM), two 0.3-cm sections of the thoracic aorta just distal to the left common carotid artery were processed by using standard protocols and embedded in Epon resin. One-micrometer thick sections were cut, stained with toluidine blue, and examined by light microscopy. Sections with detectable abnormalities were thin-sectioned, stained with uranyl acetate followed by lead citrate, and viewed by using a Phillips 301 TEM at 60 kV.
For scanning electron microscopy, the entire aortic arch from the heart to just proximal to the left common carotid was dehydrated through a graded series of ethanol solutions, treated with hexamethyldisilazane, and allowed to air-dry overnight. The samples were bisected, placed on nickel stubs, coated with a thin layer of carbon and a mixture of gold/palladium, and viewed by using a Leo (Helsingborg, Sweden) model 435VP scanning electron microscope at 20 kV. To assay vascular permeability, Evans blue (30 mg/kg) was injected into animals through the tail vein 15 min before the sacrifice (15). The ascending aorta was removed and frozen in OCT compound, and cross sections (6 µm) were prepared. Extravasation of macromolecules was evaluated under fluorescent microscopy (Nikon B2A) with an excitation filter at 400-440 nm, a dichromic mirror at 510 nm, and a barrier filter at 520 nm.| |
Results |
|---|
|
|
|---|
Inactivation of the Murine Gulo Gene. The strategy for inactivating the Gulo gene is shown in Fig. 1. A missense mutation in the Gulo gene of Osteogenic Disorder Sionogi rats that replaces cysteine at position 61 in exon 3 with tyrosine is sufficient to dramatically reduce mRNA stability and enzyme activity (9), and the Gulo gene in guinea pigs has a stop codon at codon 61 in exon 3 in addition to many other defects in exon 6 (7). There therefore can be little doubt that deletion of the sequences containing exons 3 and 4 eliminates all gene function. Even if splicing were to occur between exons 2 and 5, the reading frame is not preserved. On Southern blot analyses, DNA from the modified cells gave a 14-kb SacI fragment and a 9.5-kb HindIII fragment hybridizing to probe a in addition to 5.5-kb SacI and 8-kb HindIII endogenous fragments; probe b hybridized to a 14-kb SacI fragment in addition to the endogenous 9-kb fragment (not shown). Two chimeras generated from targeted cells transmitted the embryonic stem cell genome to their F1 pups.
Gulo-Deficient Mice Depend on Dietary Vitamin C. When heterozygous F1
animals were mated, homozygous pups (
/
) were born at the expected frequency. The homozygous mice lack Gulo gene expression
as shown in the Northern blot hybridization of total RNA isolated from the liver (Fig. 1D).
The body weights of homozygous pups born to heterozygous mothers were not
different at 21 days of age from their heterozygous and
wild-type litter mates. However, after weaning onto regular chow, which contains about 110 mg/kg
of ascorbic acid, the homozygotes grew very
little, and after 40 days of age they began to lose weight, whereas the
body weights of wild types and heterozygotes steadily increased (Fig. 2A).
In this experiment, one of the three homozygotes died on the 47th
day, but after supplementation of vitamin C in the drinking water at
330 mg/liter the remaining two began to gain weight. This amount of
vitamin C supplementation, also used in
Osteogenic Disorder Sionogi
rats (16),
allows homozygous animals to gain weight and reproduce normally, as long as they
remain on vitamin C supplementation.
|
Gulo
/
Homozygotes Have Reduced Tissue and Plasma Ascorbic Acid Levels and a Reduction in Plasma Antioxidant Capacity. Ascorbic acid levels in the plasma, liver, and brain
of the Gulo
/
homozygous mutants maintained on
unsupplemented chow for
3-5 weeks are 1.7 ± 0.2 µg/ml, 31 ± 2 µg/g, and
112 ± 14 µg/g, respectively (Fig. 3
A-C). These values are
significantly lower
(P < 0.001) than those in wild type
(11.1 ± 0.5 µg/ml, 186 ± 8 µg/g, and
511 ± 15 µg/g, respectively). The levels in heterozygotes
are also slightly lower than normal, although the difference is not statistically significant except in the plasma
(9.6 ± 0.3 µg/ml, P < 0.03).
Supplementation with 330 mg/liter of vitamin C in water normalizes the plasma levels in
heterozygotes and increases
the levels in homozygotes to
approximately 60% normal. The plasma levels in supplemented
homozygous males (5.7 ± 0.3 µg/ml,
n = 6) are significantly lower than the levels in females
(8.2 ± 0.5 µg/ml,
n = 6, P < 0.001), and a similar trend
is also present in heterozygotes (10.8 ± 0.7 vs.
12.4 ± 0.5, n = 6, not significant). Plasma ascorbic acid levels do not differ between male and
female wild-type mice.
|
Plasma Ascorbic Acid Levels Correlate Negatively with Plasma Total Cholesterol and Positively with HDL-Cholesterol Levels. Because animal and epidemiological studies have suggested an association between plasma lipid levels and ascorbic acid levels, we tested whether reduced plasma and tissue ascorbic acid levels are correlated with the plasma lipid and lipoprotein distribution in our mice. We found a significantly increased mean plasma cholesterol levels in males (Fig. 4A) and a trend toward it in females (Fig. 4B) with a decrease in the number of the functional Gulo genes. Both Gulo genotype and gender of animals significantly affected the plasma cholesterol levels in mice with the Gulo genotype explaining 7% of the variance (P < 0.01) and gender explaining 8% (P < 0.005). Significant effects on HDL cholesterol levels in 80 animals also were observed as a function of genotype (P < 0.05) and gender (P < 0.02), with each explaining 8% of the variance.
|
Rupture of Elastic Lamina, Smooth Muscle Cell Proliferation, and Injury of the Luminal Surface in the Thoracic Aorta. Ascorbic acid is an important cofactor for the hydroxylation of proline and lysine necessary for the crosslinking of collagen and elastin, important structural components of vessel wall (18, 19). Inspection under both light microscopy and TEM of cross sections of the thoracic aorta from animals with low levels of plasma and tissue ascorbic acid revealed marked alterations in the pattern and integrity of the elastic laminae. Prominent breaks and fragmentation of the elastica were located in both the superficial and deep media (Fig. 5B). The endothelial cells overlying the areas of internal elastic lamia disruption were attenuated as a result of the accumulation of basement membrane material, collagen/elastic tissue, and aggregates of smooth muscle cells. Some smooth muscle cells had an altered morphology, were devoid of cytoplasmic filaments, and contained myelin figures indicative of cellular degeneration (not shown). Small clusters of smooth muscle cells, ranging from a few to a diffuse collections of several cells, were present within the subintima below the basement membrane and above the superficial elastic lamina (Fig. 5C). Most of the smooth muscle cells present within the intima were mildly activated as judged by a slight increase in their rough endoplasmic reticulum. Small collections of elastic fibers were located between smooth muscle cells both in the intima and in the deep media, suggesting that reorganization of the elastic lamina is a dynamic process in these mice.
|
|
| |
Discussion |
|---|
|
|
|---|
Humans, as a consequence of the loss during evolution of the
enzyme, L-gulono-
-lactone oxidase, are not able to synthesize ascorbic acid, a small water-soluble antioxidant.
Mice lacking the same enzyme, like
humans, depend on dietary supplementation of vitamin C for survival. Thus, the Gulo
/
mice with 0.02 mg/g of
body weight/day of ascorbic acid intake have 10% normal plasma
ascorbic acid levels and do not live longer than
6 weeks.
In humans, the Sheffield study carried out on healthy volunteers showed
that the minimum protective dose of
vitamin C defined by the absence of clinical scurvy is 10 mg/day (20).
This result contributed
importantly to the currently recommended daily dose of
60 mg/day (0.001 mg/g of body weight/day) for humans. Recent studies by Levine et
al. (21)
have shown, however, that this daily dose maintains plasma ascorbic acid levels in healthy male
volunteers at subsaturation levels of about 25 µM; they recommended an increase in vitamin C intake to 200 mg/day, which saturates plasma level at
70 µM (12 µg/ml). The requirement of more than
0.08 mg/g per day of vitamin C to reach comparable plasma levels in the
Gulo
/
mice is probably in part caused by the species differences in metabolic rates and in plasma levels of uric acid; about 5 mg/dl in
humans (22)
and 0.9 mg/dl in mice (23).
Urate serves as a primary radical scavenger and probably helps to maintain plasma level of
ascorbic acid by inhibiting iron-catalyzed ascorbate oxidation. These
species differences also are reflected in our finding that
approximately 72% of the total
antioxidative capacity in normal mouse plasma is
accounted for by ascorbic acid, whereas ascorbic acid accounts for only 0-24% of plasma
antioxidant capacity in healthy human
nonsmokers, whereas uric acid contributes 35-65% (22).
Although we do not exclude the
possibility that Gulo
/
animals may accumulate oxidative damage in tissues or
cells after a prolonged
period with insufficient vitamin C, no elevation of lipid
peroxidation products measured by
plasma or liver malonaldehyde was detectable in homozygotes after 4 weeks
of removing vitamin C from the drinking water. This result is
not surprising, because
these mice still have 35%
normal levels of plasma total
antioxidative capacity. Whether differences in the levels of other biomarkers
can be detected (24)
or whether the mutant animals will respond differently from wild-type
mice to various stresses, such as severe inflammatory conditions, remains to be determined.
Epidemiological studies have not
been conclusive in linking vitamin C to cardiovascular diseases in humans (25).
For example, the World Health Organization/MONICA (monitering of trends and
determinants in cardiovascular diseases) study showed, on a
group level, an association of low plasma vitamin C levels with high cardiovascular mortality (26).
On the other hand, in the Health Professionals Follow-up Study, no
association could be established (27).
In mice with plasma ascorbic acid levels ranging from normal
to subnormal levels, we find that
plasma ascorbic acid levels in mice are inversely correlated with plasma cholesterol and positively with
HDL cholesterol. Similar
relationships also have been seen in some, but not all, human studies
(26,
28).
Although vitamin C deficiency in guinea pigs has been reported
to be associated with 20-40% lower levels of HDL
cholesterol (29),
the contribution of the plasma
ascorbic acid levels to the variance in HDL cholesterol levels seen in our experiments
was 10%. This contribution, although small, is
significant. In addition, the
vitamin C-deficient mice have an increase in low density
lipoprotein-size particles and a small decrease in HDL, giving them less
favorable lipoprotein profiles for cardiovascular protection than wild-type mice. The mechanisms that underlie the observed
relationship between the levels of ascorbic acid and lipoproteins in the plasma of
mice have not been determined,
but a reduction in 7-
-hydroxylase activity has been demonstrated in vitamin C-deficient guinea pigs (30-32).
Although further investigation is clearly needed, our results
re-emphasize the importance of
proper vitamin C intake to maintain a plasma lipoprotein profile
that is associated with
reduced risk for coronary heart disease.
The most striking pathological
finding in our current study is the
presence of abnormalities in the
aortic walls of the vitamin C-deficient mice. The simplest explanation of this
pathology is that the fragmentation of elastic lamina is caused by defects in the crosslinking of collagen and elastin because of the need for vitamin C to generate hydroxylysine and
hydroxyproline. Support for this explanation is provided by the
observations of similar fragmentation of elastic fibers in mice with the Blotchy allele at the X-linked
Mottled locus (33).
The Mottled locus codes for a copper-transporting ATPase, which is necessary for lysyl oxidase
activity to crosslink collagen and elastin (34).
Similar aortic wall changes also have been seen in young rats
treated with
-aminopropionitrile, an inhibitor of lysyl oxidase (35,
36).
However, although the aortic wall
abnormalities in Blotchy
mice progress to gross dilatation, aneurysm, and
aortic rupture, the
abnormalities seen in our vitamin
C-deficient mice appear to be more subtle. The lesions in the
aortic arch of vitamin C-deficient mice are longitudinal and most frequently
are seen near the takeoff of the carotid where the blood flow related
shear-stress is high. We did not find platelets, fibrin, or other
blood cells in the areas
with endothelial alteration. But there is a marked increase in the extravasation of
macromolecules into the aortic wall in these areas as
evidenced by the distribution of
Evans blue in the vitamin
C-deficient mice.
In conclusion, we have generated mice lacking L-gulono-
-lactone oxidase, a key enzyme for ascorbic acid synthesis. The mutant mice, like humans, entirely depend on
dietary vitamin C, and they show changes indicating that the integrity of their
vasculature is compromised. When combined with the batteries of mutant
mice generated in recent years, the Gulo
/
mutant mouse
should provide unique opportunities for exploring the interactions between genetic determination and
environmental factors, such as oxidative stress, and the
effects on these interactions of different levels of vitamin C in the diet.
| |
Acknowledgements |
|---|
We thank K. Kluckman, A. Staton, E. Boudyguina, and K. Gush for technical help, and Dr. O. Smithies for discussion. This work was supported by grants from the American Heart Association (9650086N) and the National Institutes of Health (HL42630).
| |
Abbreviations |
|---|
Gulo, L-gulono-
-lactone oxidase gene, HDL, high density
lipoprotein; TEM, transmission electron microscopy.
| |
Footnotes |
|---|
To whom reprint requests should be
addressed. E-mail: nobuyo@med.unc.edu.
Present address; Fujisawa Pharmaceutical Co. Ltd., Osaka,
560 Japan.
| |
References |
|---|
|
|
|---|
| 1. | Knight, J. A. (1995) Ann. Clin. Lab. Sci. 25, 111-121[ISI][Medline]. |
| 2. | Berliner, J. A. & Heinecke, J. W. (1996) Free Radical Biol. Med. 20, 707-727[CrossRef][ISI][Medline]. |
| 3. | Collins, A. R. (1999) BioEssays 21, 238-246[CrossRef][ISI][Medline]. |
| 4. | Bowling, A. C. & Beal, M. F. (1995) Life Sci. 56, 1151-1171[CrossRef][ISI][Medline]. |
| 5. | Smithies, O. & Maeda, N. (1995) Proc. Natl. Acad. Sci. USA 92, 5266-5272[Abstract]. |
| 6. | Nishikimi, M., Fukuyama, R., Minoshima, S., Shimizu, N.
& Yagi, K. (1994) J. Biol. Chem. 269, 13685-13688 |
| 7. | Nishikimi, M., Kawai, T. & Yagi, K. (1992) J. Biol.
Chem. 267,
21967-21972 |
| 8. | Mizushima, Y., Harauchi, T., Yoshizaki, T. & Makino, S. (1984) Experientia 40, 359-361[ISI][Medline]. |
| 9. | Kawai, T., Nishikimi, M., Ozawa, T. & Yagi, K. (1992)
J. Biol. Chem.
267, 21973-21976 |
| 10. | Bronson, S. K., Plaehn, E. G., Kluckman, K. D., Hagaman, J. R., Maeda, N. & Smithies, O. (1996)
Proc. Natl. Acad. Sci. USA 93, 9067-9072 |
| 11. | Omaye, S., Turnbull, J. D. & Sauberlich, H. E. (1979) Methods Enzylmol. 62, 3-11. |
| 12. | Maxwell, S. R. J., Wiklund, O. & Bondjers, G. (1994) Atherosclerosis (Shannon, Irel.) 111, 79-89. |
| 13. | Warnick, G. R., Benderson, J. & Albers, J. J. (1982) Clin. Chem. 28, 1379-1388[ISI][Medline]. |
| 14. | Zhang, S. H., Reddick, R. L., Piedrahita, J. A. & Maeda, N. (1992) Science 258, 468-471[ISI][Medline]. |
| 15. | Lin, S.-J., Jan, K.-M. & Chien, S. (1990) Arteriosclerosis 10, 703-709[Abstract]. |
| 16. | Chan, S. W. & Reade, P. C. (1996) Lab. Anim. 30, 337-346[ISI][Medline]. |
| 17. | Bernstein, S. E. (1966) in Biology of the Laboratory Mouse, ed. Green, E. L. (Dover, New York), pp. 337-350. |
| 18. | Pinnell, S. R. (1985) Yale J. Biol. Med. 58, 553-559[ISI][Medline]. |
| 19. | Peterkofsky, B. (1991) Am. J. Clin. Nutr. 54, 1135S-1140S[Abstract]. |
| 20. | Krebs, H. A. (1953) Proc. Nutr. Soc. 12, 237-246[ISI]. |
| 21. | Levine, M., Conry-Cantilena, C., Wang, Y., Welch, R. W., Washko, P. W., Dhariwal,
K. R., Park, J. B., Lazarev, A., Graumlich, J. F., King, J. & Cantilena, L. R. (1996) Proc. Natl. Acad. Sci. USA 93, 3704-3709 |
| 22. | Nyyssonen, K., Porkkala-Sarataho, E., Kaikkonen, J. & Salonen, J. T. (1997) Atherosclerosis (Shannon, Irel.) 130, 223-233[CrossRef]. |
| 23. | Wu, X., Wakamiya, M., Vaishnav, S., Geske, R., Montgomery, C., Jr., Jones, P., Bradley, A. & Caskey, C. T. (1994) Proc. Natl. Acad. Sci. USA 91, 742-746[Abstract]. |
| 24. | de Zwart, L. L., Meerman, J. H., Commandeur, J. N. & Vermeulen, N. P. (1999) Free Radical Biol. Med. 26, 202-226[CrossRef][ISI][Medline]. |
| 25. | Simon, J. A. (1992) J. Am. Coll. Nutr. 11, 107-125[Abstract]. |
| 26. | Gey, K. F., Brubacher, G. B. & Stahelin, H. B. (1987) Am. J. Clin. Nutr. 45, 1368-1377[ISI][Medline]. |
| 27. | Rimm, E. B., Stampfer, M. J., Ascherio, A., Giovannucci, E., Colgitz, G. A. & Willett, W.
C. (1993) N. Engl.
J. Med. 328, 1450-1456 |
| 28. | Jacques, P. F., Sulsky, S. I., Perrone, G. A. & Schaefer, E. J. (1994) Epidemiology 5, 19-26[ISI][Medline]. |
| 29. | Satinder, Sarkar, A. K., Majumdar, S. & Chakravarti, R. N. (1987) Indian J. Med. Res. 86, 351-360[ISI][Medline]. |
| 30. | Ginter, E., Bobek, P. & Jurcovicova, M. (1982) in Ascorbic Acid: Chemistry, Metabolism, and Uses, eds. Seib, P. A. & Tolbert, B. M. (Am. Chem. Soc., Washington, DC), pp. 381-393. |
| 31. | Holloway, D. E. & Rivers, J. M. (1981) J. Nutr. 111, 412-424[ISI][Medline]. |
| 32. | Bjorkhem, I. & Kallner, A. (1976) J. Lipid Res. 17, 360-365[Abstract]. |
| 33. | Andrews, E. J., White, W. J. & Bullock, L. P. (1975) Am. J. Pathol. 78, 199-200[Abstract]. |
| 34. | Levinson, B., Vulpe, C., Elder, B., Martin, C., Verley, F., Packman, S. & Gitschier, J. (1994) Nat. Genet. 4, 369-373. |
| 35. | Julian, M., Pieraggi, M. T. H. & Bouissou, H. (1979) Pharmacol. Res. Commun. 11, 501-501[ISI][Medline]. |
| 36. | Sauvage, M., Jacob, M. P. & Osborne-Pellegrin, M. (1997) J. Vasc. Res. 34, 126-136[ISI][Medline]. |
This article has been cited by other articles:
![]() |
N. P. Maulen, E. A. Henriquez, S. Kempe, J. G. Carcamo, A. Schmid-Kotsas, M. Bachem, A. Grunert, M. E. Bustamante, F. Nualart, and J. C. Vera Up-regulation and Polarized Expression of the Sodium-Ascorbic Acid Transporter SVCT1 in Post-confluent Differentiated CaCo-2 Cells J. Biol. Chem, March 14, 2003; 278(11): 9035 - 9041. [Abstract] [Full Text] [PDF] |
||||
|
| |||||
|
Y. Nakata and N. Maeda Vulnerable Atherosclerotic Plaque Morphology in Apolipoprotein E-Deficient Mice Unable to Make Ascorbic Acid Circulation, March 26, 2002; 105(12): 1485 - 1490. [Abstract] [Full Text] [PDF] |
|||||
|
| |||||
|
J. Armour, K. Tyml, D. Lidington, and J. X. Wilson Ascorbate prevents microvascular dysfunction in the skeletal muscle of the septic rat J Appl Physiol, March 1, 2001; 90(3): 795 - 803. [Abstract] [Full Text] |
|||||
|
| |||||
|
M.-L. Brennan, M. M. Anderson, D. M. Shih, X.-D. Qu, X. Wang, A. C. Mehta, L. L. Lim, W. Shi, S. L. Hazen, J. S. Jacob, J. R. Crowley, J. W. Heinecke, and A. J. Lusis Increased atherosclerosis in myeloperoxidase-deficient mice J. Clin. Invest., February 15, 2001; 107(4): 419 - 430. [Abstract] [Full Text] |
|||||
|
| |||||
|